Insider transactions

Michael Jay Ross

CIK 1254452 · last filed 2022-06-17

Michael Jay Ross is a corporate insider who has filed 19 SEC Form 4 insider transactions across 6 companies since 2013. The most recent filing, for XLO, was dated Jun 17, 2022. Across all open-market trades the lifetime net is +$5.0M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $210.1K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$210.1K

Companies

6

Total Filings

19

Lifetime Open-Market Net

$5.00M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

Filer Profile

Reported Address
C/O SV HEALTH INVESTORS, LLC
ONE BOSTON PLC, 201 WASHINGTON ST. #3900
BOSTON, MA 02108
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
XLO Director — $8.94 — $0 2 2022-06-17
Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Director — $25.59 — $0 2 2019-06-13
STRO Director 12,928 $16.25 $210.1K $0 2 2018-10-01
IVERIC bio, Inc. (OPHT) Delisted Director 3,500 — — $0 5 2018-07-11
Astria Therapeutics, Inc. (CATB) Delisted Director — $8.54 — $0 4 2018-06-07
X4 Pharmaceuticals, Inc (ASNS) Delisted Director 19,128 $0.08 $1.5K $5.00M 4 2018-06-07

Recent Filings

19 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-06-17 XLO Grant (A) — $0 EDGAR
2021-10-25 XLO Grant (A) — $0 EDGAR
2019-06-13 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Grant (A) — $0 EDGAR
2018-10-01 STRO Mixed +1,824,542 $0 EDGAR
2018-09-27 STRO Grant (A) — $0 EDGAR
2018-07-11 IVERIC bio, Inc. (OPHT) Delisted Grant (A) — $0 EDGAR
2018-06-07 Astria Therapeutics, Inc. (CATB) Delisted Grant (A) — $0 EDGAR
2018-06-07 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
2018-05-21 Deciphera Pharmaceuticals, Inc. (DCPH) Delisted Grant (A) — $0 EDGAR
2018-03-05 X4 Pharmaceuticals, Inc (ASNS) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 19
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.